PD36-12 DOES MIRABEGRON HAVE A POSITIVE IMPACT ON SEXUAL FUNCTION IN FEMALES WITH OVERACTIVE BLADDER?

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Female (PD36)1 Apr 2020PD36-12 DOES MIRABEGRON HAVE A POSITIVE IMPACT ON SEXUAL FUNCTION IN FEMALES WITH OVERACTIVE BLADDER? Samer Morsy, Hussein Hussein*, Dalia Abdel Azim, Sarah Hassan, and Eman Hussein Samer MorsySamer Morsy More articles by this author , Hussein Hussein*Hussein Hussein* More articles by this author , Dalia Abdel AzimDalia Abdel Azim More articles by this author , Sarah HassanSarah Hassan More articles by this author , and Eman HusseinEman Hussein More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000907.012AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Overactive bladder (OAB) may be associated with unpleasent effect on female sexual function. Mirabegron, a β3 receptor agonist, improves OAB symptoms, but there is limited information about its role on female sexual dysfunction (FSD). Aim of the study was to assess the impact of Mirabegron on FSD in women affected by idiopathic OAB. METHODS: One hundred sexually active women suffering from idiopathic OAB were included in the study. Patients were assessed by means of a urogynecologic physical examination and were asked to complete the 3-day voiding diary, the International Consultation on Incontinence Questionnaire- Short Form (ICIQ-SF), the Female Sexual Function Index (FSFI) questionnaire and VAS, before and 12 weeks after treatment with Mirabegron 50 mg once daily dose. In addition, at the same time points, patients underwent uroflowmetry with the measurement of post- void residual volume (PVR). RESULTS: At baseline all patients were affected by OAB symptoms, with 98/100 patients (98%) presenting with FSD. At 12- weeks follow- up, OAB symptoms improved significantly in all patients, with 59.5% of subjects achieving a complete urinary continence. FSFI Total Score significantly improved in 84/100 patients (84%) from 18.9 ± 4.3 to 21.8 ± 4.5 (p < 0.0001). Thirty two cases (32%) presented with no FSD. Also mean ± SD scores of ICIQ-SF and VAS significantly improved (from 17.1 ± 5 to 7.9 ± 4.8 and from 3.9 ± 1.2 to 6.9 ± 1.2 respectively, p < 0.000). CONCLUSIONS: Mirabegron 50 mg control urinary symptoms in women with OAB, and also induces a significant improvement in their sexual life. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e727-e727 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Samer Morsy More articles by this author Hussein Hussein* More articles by this author Dalia Abdel Azim More articles by this author Sarah Hassan More articles by this author Eman Hussein More articles by this author Expand All Advertisement PDF downloadLoading ...